Skip to main content

Table 3 Clinical characteristics of PNH patients at baseline

From: Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria

Variable Began trial on eculizumab (n = 219) Began trial on ravulizumab (n = 222)
Trial 301 Trial 302 Trial 301 Trial 302
# % # % # % # %
Observed LDH Category         
 LDH < 1.5×ULN 0 0 98 100 0 0 97 100
 LDH 1.5–< 3×ULN 16 13 0 0 18 14 0 0
 LDH ≥ 3×ULN 105 87 0 0 107 86 0 0
Observed pRBC stratum         
 0 unit pRBC 21 17 NA   22 18 NA  
 1–14 units pRBC 76 63    80 64   
 > 14 units pRBC 24 20    23 18   
Immuno-suppressant treatment 14 12 98 100 15 12 97 100
Aplastic anemia 38 31 39 40 41 33 34 35
Myelodysplastic syndrome 6 5 6 6 7 6 3 3
Bone marrow disorder 43 36 42 43 46 37 35 36
Derived PNH risk-factor group         
 Higher 107 88 0 0 110 88 0 0
 Lower 14 12 98 100 15 12 97 100
  Mean SD Mean SD Mean SD Mean SD
Derived PNH risk-factor index 9.21 0.93 6.46 0.56 9.22 0.87 6.38 0.53